# LIFEMEL Efficacy in Preventing Haematopoietic Toxicity in Patients Treated With Chemotherapy

> **NCT04562922** · PHASE2 · COMPLETED · sponsor: **VitalMel** · enrollment: 39 (actual)

## Conditions studied

- Neutropenia
- Adverse Event

## Interventions

- **DIETARY_SUPPLEMENT:** Lifemel

## Key facts

- **NCT ID:** NCT04562922
- **Lead sponsor:** VitalMel
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-11
- **Primary completion:** 2014-05-26
- **Final completion:** 2016-04-04
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2020-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04562922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04562922, "LIFEMEL Efficacy in Preventing Haematopoietic Toxicity in Patients Treated With Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04562922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*